Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Glioblastoma 69Glioma 26Brain Neoplasms 26Gliosarcoma 23Melanoma 17Central Nervous System Neoplasms 14Astrocytoma 12Neuroblastoma 10Rhabdomyosarcoma 8Small Cell Lung Carcinoma 6Sarcoma, Ewing 6Neoplasms 6Neoplasm Metastasis 6Medulloblastoma 6Recurrence 5Sarcoma 4Ovarian Neoplasms 4Osteosarcoma 4Oligodendroglioma 4Wilms Tumor 3Prostatic Neoplasms 3Neuroectodermal Tumors, Primitive, Peripheral 3Ependymoma 3Diffuse Intrinsic Pontine Glioma 3Breast Neoplasms 3Rhabdoid Tumor 2Pancreatic Neoplasms 2Optic Nerve Glioma 2Lymphoma, Follicular 2Lymphoma 2

Interventions

pazopanib 1Temozolomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Islet Cell × Temozolomide × Clear all
NCT01465659 2021-08-05

Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery

Northwestern University

Phase 1/2 Completed
29 enrolled 16 charts

Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡